Articles From: Synchrony IPO priced at low end of expectations to Synovus Announces Stock Dividend For Series C Preferred Stock


2014/7/31
By Matt Jarzemsky Shares of private-label credit-card business sold for $23 -Matt Jarzemsky; 415-439-6400; AskNewswires@dowjones.com Credit-card issuer Synchrony Financial's initial public offering, the biggest in the U.S. this year, priced at the low end of expectations, a sign of tepid demand for the latest company to offer investors a way to play the recovery in consumers' finances.
Sign-up for Synchrony IPO priced at low end of expectations investment picks
2014/7/31
By Ciara Linnane, MarketWatch Shares of General Electric spinoff Synchrony Financial got off to a lackluster start on their first day of trading on Thursday, opening at their issue price of $23 and meandering in the first hour of trade.
Sign-up for Synchrony off to lackluster start in stock debut investment picks
2014/7/22
NEW YORK , July 22, 2014 /PRNewswire/ -- Syncora Holdings Ltd.
Sign-up for Syncora Holdings Ltd. Announces Director Re-elections at Annual General Meeting of Shareholders investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its lead drug plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). Agreement was reached with the FDA for the plecanatide pivotal phase 3 IBS-C clinical development program that is scheduled to begin in the fourth quarter of this year.
Sign-up for Synergy Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Plecanatide in Irritable Bowel Syndrome with Constipation investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed patient enrollment for its phase 2 trial of SP-333, Synergy’s next-generation uroguanylin analog, in patients with opioid-induced constipation (OIC). The multi-center, randomized, double-blind clinical trial is designed to compare a 4-week dose-ranging regimen of once-daily oral SP-333 (1.0 mg, 3.0 mg and 6.0 mg) against placebo in patients taking opioid analgesics for chronic, non-cancer pain for at least three months.
Sign-up for Synergy Pharmaceuticals Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC). The trial is currently being conducted at 180 sites and has randomized approximately 675 CIC patients.
Sign-up for Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today reported its financial results and business update for the three and six months ended June 30, 2014.
Sign-up for Synergy Pharmaceuticals Reports Second Quarter and First Half 2014 Financial Results investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr.
Sign-up for Synergy Pharmaceuticals to Present at Canaccord Genuity Growth Conference investment picks
Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions New Device Featured in Upcoming Presentation by Dr.
Sign-up for Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions investment picks
New Device Featured in Upcoming Presentation by Dr.
Sign-up for Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions investment picks
YOKNEAM, Israel , July 25, 2014 /PRNewswire/ -- Syneron Medical Ltd.
Sign-up for Syneron Announces Investor Meeting Focused on UltraShape U.S. Launch Update on September 17, 2014 investment picks
Fungus Indication Expands Functionality of Gentle Pro Laser Series IRVINE, Calif.
Sign-up for Syneron Medical Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosis investment picks
YOKNEAM, Israel , July 18, 2014 /PRNewswire/ -- Syneron Medical Ltd.
Sign-up for Syneron Medical to Report Second Quarter 2014 Financial Results on August 6, 2014 investment picks
Award Winning Product Enters World's Largest Market with First-of-its-kind, Skin Brightening Lotion BEIJING , July 21, 2014 /PRNewswire/ -- Syneron Medical Ltd.
Sign-up for Syneron Receives China CFDA Clearance for elure™ Advanced Skin Brightening Lotion investment picks
Revenue of $64.6 million; non-GAAP EPS $0.07 UltraShape commercial launch accelerated to Q4 2014 Received CE Mark for PicoWay, enhancing position in tattoo removal and treatment of pigmented lesions YOKNEAM, Israel , Aug.
Sign-up for Syneron Reports Second Quarter 2014 Results investment picks
2014/6/17
- Grower access to best malting barley varieties and agronomic support - Protocol helps growers achieve consistent yield and quality increases - Aim to scale up first phase and transfer initiative to other markets BASEL, Switzerland and BRUSSELS , June 17, 2014 /PRNewswire/ -- Syngenta and Anheuser-Busch InBev (AB InBev) announced today a partnership to secure the sourcing of high-quality malting barley, the key raw material for the beer industry.
Sign-up for Syngenta and Anheuser-Busch InBev enter malting barley collaboration investment picks
LONDON (MarketWatch) -- Shares in agrochemicals maker Syngenta (ch:synn) were up 4.5% after a Bloomberg report Tuesday that Monsanto Co.
Sign-up for Syngenta shares rise on report of Monsanto talks investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Synnex Corp.
Sign-up for Synnex shares decline as outlook edges earnings investment picks
Collaboration enables stochastic modeling of device degradation and reliability through industry leading Sentaurus Device TCAD simulator MOUNTAIN VIEW, Calif.
Sign-up for Synopsys and IIT Bombay Collaborate on Reliability Modeling of Advanced Transistors investment picks
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Earnings Release Date for Third Quarter Fiscal Year 2014 investment picks
New Program Provides Prototypers with Daughter Boards and Services from Synopsys-Approved Third Party Providers MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces HAPS Connect Program to Speed Creation of HAPS FPGA-Based Prototypes investment picks
Production-Ready DesignWare IP for TSMC 28HPC Process Enables Designers to Reduce Power Consumption and Area for Mobile and Ultra Low-Power IoT Designs MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Immediate Availability of Broad Portfolio of IP for TSMC 28HPC Process investment picks
2014/8/25
Annual Competition Recognizes Student Achievements in Optical Design MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Results of Robert S. Hilbert Memorial Optical Design Competition investment picks
New Trim NVM IP Leverages Faster Programming Times to Reduce NVM Test Time by 3X Without Compromising AEC-Q100 Quality MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Cuts Area of DesignWare NVM IP for Automotive Grade 0 Applications by 75 Percent investment picks
Use of Silicon-Proven DesignWare USB IP by More than 60 Companies Demonstrates High Quality and Low Integration Risk MOUNTAIN VIEW, Calif.
Sign-up for Synopsys DesignWare USB 3.0 IP Shipped in More Than 100 Million Production SoCs investment picks
Protocol test suites in SystemVerilog source code accelerate compliance testing of Ethernet, USB, PCI Express, ARM AMBA AXI and MIPI CSI-2 protocols MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Expands Verification IP Portfolio with Compliance Test Suites investment picks
Q3 2014 Financial Highlights - Revenue: $521.8 million - GAAP earnings per share: $0.42 - Non-GAAP earnings per share: $0.65 MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Posts Financial Results for Third Quarter Fiscal Year 2014 investment picks
Synopsys, Inc. (Nasdaq:SNPS) , a global leader providing software, IP and services used to accelerate innovation in chips and electronic systems, will showcase DesignWare® IP for USB 3.1 and PCI Express® 4.0 at the Intel Developer Forum (IDF) in San Francisco, California from September 9-11 .
Sign-up for Synopsys Showcases DesignWare IP Solutions for USB 3.1 and PCI Express 4.0 at Intel Developer Forum 2014 investment picks
2014/9/3
Synovus Financial Corp.
Sign-up for Synovus Announces Stock Dividend investment picks
Synovus Financial Corp.
Sign-up for Synovus Announces Stock Dividend For Series C Preferred Stock investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Synchrony IPO priced at low end of expectations to Synovus Announces Stock Dividend For Series C Preferred Stock
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices